[Efficacy of Urapidil in treating lower urinary tract symptoms in patients with benign prostatic hyperplasia: A systematic review and meta-analysis].

OBJECTIVE: To investigate the potential application of α-1 blocker (urapidil) in the treatment of lower urinary tract symptoms (LUTS) in male patients with benign prostatic hypertrophy (BPH), we conducted a comprehensive meta-analysis. METHODS: Our study involved identifying and collecting randomized controlled trials (RCT) and clinical observational studies from databases including PubMed、MEDLINE、Web of science、CNKI and Wanfang database. We performed meta-analysis using RevMan 5.2.0 software for both fixed effects model and random effects model. RESULTS: Our analysis included 3 short-term (within 1 month) observational studies and 1 RCT involving 142 patients. We found that urapidil significantly improved the International Prostate Symptom Score (IPSS, MD=－5.57, 95%CI: －7.98～－3.16，P<0.00001), nocturia（MD=－0.7, 95%CI: －1.16～－0.24，P=0.003）, residual urine rate（MD=－6.97；95%CI: －12.57～－1.37，P=0.01）, average flow rate（MD=2.04；95%CI: 0.52～3.56，P=0.008）, and maximum flow rate （MD=4.29；95%CI: 0.58～8.01，P=0.02）of patients. However, there was no significant difference in the residual urine volume（MD=－35.93；95%CI: －78.62～6.76，P=0.10）between pre-treatment and post-treatment groups. CONCLUSION: Urapidil is an effective medication for relieving LUTS in BPH patients. However, due to the limited quantity and quality of current RCT studies, high-quality and large-scale RCT studies are still needed to further confirm this conclusion.